Ann: Successful Completion of Phase 1b Breast Cancer Trial, page-17

Agree AMS, it seem out of conventional in SP/ progress ratio to me as well
Some concerns follow
Heavy selling for a few months now, obviously no association to bad news leaking, actually news was the opposite to that
Also, heavy resistance setting somewhat subdue any incentive for traders, as they often opt to that pattern of trade
Only one other bio in ASX that also has imminent data to follow at their end of phase 2, results due in two weeks...., maybe a dual vesting?
One concern that Philly brought up, when placement was offered, was the size of registry taken and, I suppose we can add control of not only voting power ( say, a take over bid hostile or other) but furthermore SP guidance
Perplexed? Yes
Paranoid? Not test
I'm sure that our CEO has an interest and a tab of trading
Time will tell, as always, but certainly the SP is not reflective of the science.